Yesterday marked the beginning of the 3rd quarter. This is the make or break quarter for AERI. I'm betting big on the Make! NDA for rhopressa and Top Line for Roclatan which has the potential to be a $1-2B blockbuster. Expecting both to be announced in the late August to early September timeframe.